Abstract:
Mineral and bone
disorders in chronic kidney disease (CKD-MBD)
are among the most common and severe
complications in patients with renal
insufficiency. Fibroblast Growth Factor 23
(FGF23) is an osteocytic hormone that regulates
phosphate metabolism and vitamin D
homeostasis. Its levels begin to rise in the early
stages of CKD and have systemic effects on
mineral balance. Excessive FGF23 production
disrupts bone mineralization, exacerbates
hypophosphatemia, reduces the synthesis of
active vitamin D, and is associated with an
increased risk of cardiovascular complications.
Studying the role of FGF23 in the pathogenesis
of CKD-MBD is of high clinical importance for
diagnosis, monitoring, and therapeutic strategy
selection
